FDA officially has a new boss. The U.S. Senate voted 72-18 on Thursday to confirm Stephen Hahn, MD, as the new FDA Commissioner. The news was largely well received by industry advocacy groups like AdvaMed and professional societies like the American Heart Association.
“Dr. Hahn is an excellent choice to lead FDA, and we congratulate him on his swift and overwhelming bipartisan confirmation," said AdvaMed CEO Scott Whitaker. "During the confirmation process, Dr. Hahn demonstrated his deep understanding of the agency’s mission to protect and promote the public health and the role of innovation in improving patient care. His background as a physician, researcher and administrator will serve the American people well at this vital agency. We look forward to working with him on behalf of the patients our industry serves.”
Stephen Hahn, the chief medical executive at the University of MD Anderson Cancer Center, has been tapped by President Trump to be the new FDA commissioner. Hahn is a radiation oncologist who specializes in treating lung cancer and sarcoma.
"As a cancer researcher and oncologist, Dr. Hahn understands the need to do everything we can to ensure another generation is not addicted to tobacco products, including an increased focus on harmful e-cigarette and vaping devices," said Sen. Lisa Murkowski (R-AK). "... It's encouraging to know that Dr. Hahn recognizes the importance of providing access to promising new therapies for devestating diseases such as ALS as well as the significance of including the patient in the development process. Bottom line, he has the experience necessary to fulfill this role."
And of course the news was welcomed by many of Hahn's colleagues, including Peter WT Pisters, MD, president of The University of Texas MD Anderson Cancer Center.
"... Steve's passion for patient health and innovation will be a true benefit to the nation," Pisters said.